Targeted Diagnostics Opportunity to position ProterixBio as a partner for clinical test development and assay validation across inflammation, immune response, COPD, diabetes, and cardiovascular disease, leveraging their CLIA-certified lab and remote blood collection capabilities.

High-Complexity CLIA Leverage their established CLIA-certified high-complexity lab to offer contract testing services, assay development for clinical trials, and validation in large curated cohorts for biopharma and academic collaborations.

Serology Expansion Capitalize on past COVID-19 serology achievements and DBS finger-stick validation to propose scalable serology and biomarker panels for population health studies and chronic disease risk stratification.

Biomarker Algorithms Highlight their development of multi-biomarker algorithms to identify high-risk individuals, offering HealthTech and payer-ready risk stratification tools and analytics partnerships.

Strategic Partnerships Position as a collaborator with academic medical centers and large patient cohorts to co-develop diagnostic solutions, expanding into remote sample collection, longitudinal studies, and population health initiatives.